TrialBritish journal of haematology2015

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.

Jonathon B Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.